• Granite Asia co-led Craif’s Series D financing of about $34 million to support a US launch of a urine-based cancer test.
• Craif is a Japan-founded bio-AI company developing urine analysis for early cancer detection using microRNA and artificial intelligence.
• Round included about $30.7 million in equity, about $3.3 million in debt; total capital raised since 2018 reached about $90 million.
• Proceeds earmarked for US R&D, reimbursement-focused commercialization, Japanese regulatory filing for a pancreatic cancer software-based medical device program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Granite Asia Capital Pte Ltd. published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.